These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 29582559)

  • 1. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
    Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
    J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.
    Tiede A; Brand B; Fischer R; Kavakli K; Lentz SR; Matsushita T; Rea C; Knobe K; Viuff D
    J Thromb Haemost; 2013 Apr; 11(4):670-8. PubMed ID: 23398640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).
    Klamroth R; Feistritzer C; Friedrich U; Lentz SR; Reichwald K; Zak M; Chowdary P
    J Thromb Haemost; 2020 Feb; 18(2):341-351. PubMed ID: 31618804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
    Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
    Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.
    Stennicke HR; Kjalke M; Karpf DM; Balling KW; Johansen PB; Elm T; Øvlisen K; Möller F; Holmberg HL; Gudme CN; Persson E; Hilden I; Pelzer H; Rahbek-Nielsen H; Jespersgaard C; Bogsnes A; Pedersen AA; Kristensen AK; Peschke B; Kappers W; Rode F; Thim L; Tranholm M; Ezban M; Olsen EH; Bjørn SE
    Blood; 2013 Mar; 121(11):2108-16. PubMed ID: 23335368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
    Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
    Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
    Hampton K; Chowdary P; Dunkley S; Ehrenforth S; Jacobsen L; Neff A; Santagostino E; Sathar J; Takedani H; Takemoto CM; Négrier C
    Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
    Curry N; Albayrak C; Escobar M; Andre Holme P; Kearney S; Klamroth R; Misgav M; Négrier C; Wheeler A; Santagostino E; Shima M; Landorph A; Tønder SM; Lentz SR
    Haemophilia; 2019 May; 25(3):373-381. PubMed ID: 30817066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model.
    Pastoft AE; Ezban M; Tranholm M; Lykkesfeldt J; Lauritzen B
    Haemophilia; 2013 Nov; 19(6):913-9. PubMed ID: 23730746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.
    Chowdary P; Carcao M; Holme PA; Jiménez-Yuste V; Lentz SR; Møss J; Poulsen LH; Shen C; Tosetto A; Wheeler A; Santagostino E
    Res Pract Thromb Haemost; 2019 Jul; 3(3):542-554. PubMed ID: 31294338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.
    Agersø H; Stennicke HR; Pelzer H; Olsen EN; Merricks EP; Defriess NA; Nichols TC; Ezban M
    Haemophilia; 2012 Nov; 18(6):941-7. PubMed ID: 22812621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates.
    Lunghi B; Bernardi F; Martinelli N; Frusconi S; Branchini A; Linari S; Marchetti G; Castaman G; Morfini M
    J Thromb Haemost; 2019 Aug; 17(8):1288-1296. PubMed ID: 31055871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
    Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
    J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
    Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
    J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
    Vargas Christensen I; Loftager M; Rode F; Mørck Nielsen H; Kreilgaard M; Larsen MS
    J Thromb Haemost; 2019 Jun; 17(6):964-974. PubMed ID: 30924607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
    Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
    Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
    Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
    J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor VIII with a 237 amino acid B-domain has an extended half-life in F8-knockout mice.
    Bloem E; Karpf DM; Nørby PL; Johansen PB; Loftager M; Rahbek-Nielsen H; Petersen HH; Blouse GE; Thim L; Kjalke M; Bolt G
    J Thromb Haemost; 2019 Feb; 17(2):350-360. PubMed ID: 30525289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
    Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
    Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.